Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P01178 (
oxytocin
)
15,767
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The effect of an
atrial natriuretic peptide
on the secretion of the neurohypophysial peptides arginine vasopressin (AVP) and
oxytocin
has been studied in vivo and in vitro. Atriopeptin III was administered intracerebroventricularly to conscious rats and plasma concentrations of AVP and
oxytocin
were determined both in controls and in rats which had their drinking water replaced by 2% NaCl. The release of both AVP and
oxytocin
was inhibited when basal levels were increased by the saline treatment. The inhibition of AVP release lasted for 40 min whereas
oxytocin
release was inhibited for 10 min only. In a further experiment the stimulated release of AVP and
oxytocin
from the isolated neurointermediate lobe of the rat was also inhibited by atriopeptin III.
...
PMID:Atrial natriuretic factor inhibits the stimulated in-vivo and in-vitro release of vasopressin and oxytocin in the rat. 295 Jan 95
The changes in blood glucose, plasma
oxytocin
, plasma vasopressin, plasma
atrial natriuretic peptide
, serum osmolality, haematocrit and blood pressure were measured in response to acute insulin-induced hypoglycaemia in six normal male subjects. After the i.v. administration of insulin (0.15 U/kg), plasma concentrations of
oxytocin
and vasopressin increased rapidly in all subjects and were maximal 15 min after the acute hypoglycaemic reaction (R). Haematocrit increased at the time of the hypoglycaemic reaction, but there was no change in serum osmolality. Systolic blood pressure rose and diastolic blood pressure fell, but mean arterial blood pressure remained unchanged. No changes were demonstrated in plasma concentrations of
atrial natriuretic peptide
. The release of
oxytocin
and vasopressin in response to acute hypoglycaemia in man is probably caused by stimulation of the posterior pituitary gland via hypothalamic activation, and not by stimulation of osmoreceptors or baroreceptors.
...
PMID:Plasma oxytocin, arginine vasopressin and atrial natriuretic peptide responses to insulin-induced hypoglycaemia in man. 295 4
The effect of the intracerebroventricular (i.c.v.) injection of hypertonic sodium chloride on plasma
atrial natriuretic peptide
(
ANP
) and
oxytocin
(OT) was evaluated in conscious freely moving rats. A hypertonic or isotonic NaCl solution was injected into the third ventricle. Blood pressure and heart rate were monitored and blood samples were collected. I.c.v. injection of the hypertonic solution resulted in a significant increase in mean arterial pressure (105.3 +/- 2.9 mmHg at time 0 to 124.2 +/- 4.4 mmHg at 5 min, P less than 0.01) and heart rate (350.0 +/- 25.0 bpm at time 0 to 420.8 +/- 13.6 bpm at 20 min, P less than 0.01). Plasma OT increased 4-fold over the basal values 5 min after the injection (4.5 +/- 1.1 to 20.1 +/- 3.2 pg/ml, P less than 0.01), while there was no significant change in plasma
ANP
(37.3 +/- 9.1 to 46.6 +/- 12.6 pg/ml, n.s.). The control injection produced no significant changes in any parameters. These results show that hemodynamic changes are not necessarily associated with alterations in plasma
ANP
. Furthermore they suggest that central osmoreceptors are not involved in the control of
ANP
secretion.
...
PMID:Effect of central hypertonic stimulation on plasma atrial natriuretic peptide and oxytocin in conscious rats. 297 58
Our previous studies have shown that stimulation of the anterior ventral third ventricular region increases
atrial natriuretic peptide
(
ANP
) release, whereas lesions of this structure, the median eminence, or removal of the neural lobe of the pituitary block
ANP
release induced by blood volume expansion (BVE). These results indicate that participation of the central nervous system is crucial in these responses, possibly through mediation by neurohypophysial hormones. In the present research we investigated the possible role of
oxytocin
, one of the two principal neurohypophysial hormones, in the mediation of
ANP
release.
Oxytocin
(1-10 nmol) injected i.p. caused significant, dose-dependent increases in urinary osmolality, natriuresis, and kaliuresis. A delayed antidiuretic effect was also observed. Plasma
ANP
concentrations increased nearly 4-fold (P < 0.01) 20 min after i.p.
oxytocin
(10 nmol), but there was no change in plasma
ANP
values in control rats. When
oxytocin
(1 or 10 nmol) was injected i.v., it also induced a dose-related increase in plasma
ANP
at 5 min (P < 0.001). BVE by intra-atrial injection of isotonic saline induced a rapid (5 min postinjection) increase in plasma
oxytocin
and
ANP
concentrations and a concomitant decrease in plasma arginine vasopressin concentration. Results were similar with hypertonic volume expansion, except that this induced a transient (5 min) increase in plasma arginine vasopressin. The findings are consistent with the hypothesis that baroreceptor activation of the central nervous system by BVE stimulates the release of
oxytocin
from the neurohypophysis. This
oxytocin
then circulates to the right atrium to induce release of
ANP
, which circulates to the kidney and induces natriuresis and diuresis, which restore body fluid volume to normal levels.
...
PMID:Oxytocin mediates atrial natriuretic peptide release and natriuresis after volume expansion in the rat. 764 11
These studies evaluated the involvement of central
oxytocin
(OT) and
atrial natriuretic peptide
(
ANP
) receptors in the osmotic inhibition of hypovolemia-induced salt appetite. Rats were pretreated centrally with the A chain of the cytotoxin ricin conjugated to OT (rAOT) or
ANP
(rAANP) to selectively inactivate cells bearing these respective receptors, or rats were pretreated with the unconjugated A chain (rA) as a control. Hypovolemia was induced with subcutaneous colloid injections, and rats then were given either 2 M mannitol, which raises plasma osmolality but lowers plasma sodium, or 1 M NaCl, which raises both. Hypertonic mannitol inhibited saline ingestion in rA-treated control rats but stimulated ingestion in rAOT- and rAANP-treated rats, whereas hypertonic NaCl blunted saline ingestion in rA- and rAOT-treated rats but stimulated ingestion in rAANP-treated rats. Angiotensin II-induced saline intake was similarly potentiated in rAOT- and rAANP-treated rats, indicating that this treatment also activates central inhibitory OT and
ANP
pathways. These data suggest that central
ANP
receptors mediate both Na(+)- and osmolality-induced inhibition of NaCl ingestion, whereas central OT receptors primarily mediate osmolality-induced inhibition of NaCl ingestion in rats.
...
PMID:Central oxytocin and ANP receptors mediate osmotic inhibition of salt appetite in rats. 765 44
Sheep which were predominantly urinary excretors (U) or faecal excretors (F) of sodium were exposed to a 75% reduction of water intake for 72 h. The experiment was performed on moderate, low or high sodium intakes (0.4, 0.05 or 1.2 mmol kg-1 day-1) to test the hypothesis that dehydration natriuresis was not a cause of sodium depletion but a defence against hypernatraemia. Dehydration caused elevation of plasma sodium concentration, osmolality, antidiuretic hormone (ADH) and
oxytocin
but, as in other experiments, a fall in haematocrit. The two higher levels of sodium intake were associated with dehydration natriuresis but also a smaller increase in faecal sodium excretion in both U and F sheep. On low sodium intake, however, neither urinary nor faecal sodium excretion increased in either group of sheep although the rise in plasma sodium concentration caused by dehydration was similar. Thus, when there is a risk of sodium depletion, due to low sodium intake, dehydration natriuresis does not occur, consistent with the hypothesis. Active sodium transport inhibitor (ASTI) and
atrial natriuretic peptide
(
ANP
) fell rather than rose during dehydration. Since aldosterone is suppressed by the higher levels of sodium intake, none of these hormones is likely to mediate dehydration natriuresis in sheep. F sheep showed more effective renal and faecal water conservation when dehydrated. During water restriction, the urinary potassium excretion of U sheep was significantly reduced, unlike that of F sheep; moreover, the latter maintained an identical plasma potassium concentration between baseline and restriction period, whereas in U sheep it was 0.3 mmol l-1 higher during water restriction. Increased drinking rather than reduced urine output was the basis of rehydration when ad lib. water intake was restored.
...
PMID:Responses to reduced water intake, including dehydration natriuresis, in sheep excreting sodium predominantly in urine or in faeces. 778 17
Thyrotropin-releasing hormone,
oxytocin
, neurotensin, calcitonin gene-related peptide and neuropeptide Y have been proposed as putative neurotransmitters in the rostral ventrolateral medulla of the rat. To investigate the modulation of the basal blood pressure by neuropeptides, we microinjected these neuropeptides into the rostral ventrolateral medulla of the rat and examined their effects on basal blood pressure. Male Wistar rats were anesthetized with urethane, paralyzed and artificially ventilated. Thyrotropin-releasing hormone (0.01-1 ng),
oxytocin
(1 and 10 ng), neurotensin (0.1-10 ng), calcitonin gene-related peptide (1 and 10 ng) and neuropeptide (1 and 10 ng) produced increases in blood pressure and/or heart rate. Ganglion blockade with hexamethonium (10 mg/kg, i.v.) blocked the pressor responses to thyrotropin-releasing hormone (0.1 ng),
oxytocin
(10 ng) and neurotensin (10 ng), while methylatropine (1 mg/kg, i.v.) did not affect these responses. Corticotropin-releasing factor (0.1-10 ng) and
atrial natriuretic peptide
(1 and 10 ng) were ineffective. These findings indicate that many neuropeptides can modify basal blood pressure when injected into the rostral ventrolateral medulla. Whether these neuropeptides play a role in the blood pressure regulation within this brain region remains to be established.
...
PMID:Cardiovascular effects of microinjections of thyrotropin-releasing hormone, oxytocin and other neuropeptides into the rostral ventrolateral medulla of the rat. 821 15
A study was performed investigating the daily patterns of hormone release accompanying changes in fluid balance in the male rat during 48 h of dehydration. The blood volume decreased by 18%, the largest change occurring during the initial period when the rats showed an effective loss of body sodium. During the second day of dehydration, sodium retention was again seen. Plasma sodium concentrations showed a progressive increase, the total rise being 5-6%; the greatest changes were seen during the dark phases of the cycle which may be due to the nocturnal food intake. Plasma vasopressin and
oxytocin
concentrations were significantly elevated throughout dehydration to levels which could be reproduced by acutely increasing plasma sodium and decreasing blood volume to the same extent. The observed increases were influenced by the phase of the day-night cycle, being greatest over the dark phases of the cycle. The overall increases were greatest when dehydration commenced at the start of the dark phase. Dehydration initially led to a rise in plasma corticosterone concentrations, whilst plasma concentrations of
atrial natriuretic peptide
were decreased. Plasma angiotensin II concentrations rose significantly during the later period of sodium retention.
...
PMID:Patterns of neurohypophysial hormone release during dehydration in the rat. 832 57
Endothelin-1 (ET-1) has potent vasoconstrictor effects and thus may be involved in regulating fetoplacental vascular resistance. By using quantitative in vitro autoradiography, the 125I-ET-1 binding sites in human placentas and umbilical vessels were localized and quantified. A high density of specific 125I-ET-1 binding sites was found in the placental villi and vessels. In the media of umbilical vessels, affinity for the peptide was higher in arteries than in veins. In all structures, 125I-ET-1 binding was inhibited with unlabeled ET-1 in the picomolar range. Unrelated peptides such as
oxytocin
or
atrial natriuretic peptide
failed to compete for 125I-ET-1 binding. The localization of binding sites points to a regulation of hemodynamic functions of ET-1 on the fetal side of the placental circulation and supports evidence regarding ET-1 as a paracrine-acting vasoconstrictor.
...
PMID:Visualization of 125I-endothelin-1 binding sites in human placenta and umbilical vessels. 833 Jul 64
In order to determine which peptides are involved in modulating intrinsic cardiac neurons, angiotensin II,
atrial natriuretic peptide
, bradykinin, calcitonin gene-related peptide, enkephalin, neuropeptide Y,
oxytocin
, substance P, and vasoactive intestinal peptide dissolved in saline were administered individually by microinjection adjacent to spontaneously active canine intrinsic cardiac neurons. No neuronal or cardiac responses were elicited when saline was administered into active loci or when peptides were administered into loci with no spontaneous activity. Each peptide elicited neuronal responses when administered into active loci in most animals, bradykinin eliciting neuronal responses in every active locus studied. Concomitant cardiovascular responses were elicited in many cases when every peptide except atriopeptin was studied. After cardiac decentralization, neuronal and cardiovascular responses to repeat doses of peptides occurred with less frequency than before decentralization, implying that connections with central and other intrathoracic neurons can influence the function of peptide-sensitive intrinsic cardiac neurons. After atropine and timolol administration, cardiovascular, but not neuronal, responses to peptides were eliminated, indicating that cardiovascular responses were dependent upon efferent parasympathetic and sympathetic neurons. It is concluded that a number of neuropeptides may be involved in regulation of cardiac function by intrinsic cardiac neurons.
...
PMID:Peptidergic modulation of in situ canine intrinsic cardiac neurons. 848 97
<< Previous
1
2
3
4
5
6
7
8
9
Next >>